4,5-MDO-DMT

Last updated

4,5-MDO-DMT
4,5-MDO-DMT.svg
Clinical data
Other names4,5-Methylenedioxy-N,N-dimethyltryptamine
ATC code
  • None
Pharmacokinetic data
Onset of action Unknown [1]
Duration of action Unknown [1]
Identifiers
  • 2-(2H,6H-[1,3]dioxolo[4,5-e]indol-8-yl)-N,N-dimethylethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C13H16N2O2
Molar mass 232.283 g·mol−1
3D model (JSmol)
Melting point 93 to 95 °C (199 to 203 °F) [2]
  • CN(C)CCC1=CNC2=C1C(OCO3)=C3C=C2
  • InChI=1S/C13H16N2O2/c1-15(2)6-5-9-7-14-10-3-4-11-13(12(9)10)17-8-16-11/h3-4,7,14H,5-6,8H2,1-2H3
  • Key:ZMKRWFZFMOKVCP-UHFFFAOYSA-N
 X mark.svgNYes check.svgY  (what is this?)    (verify)

4,5-MDO-DMT, or 4,5-methylenedioxy-N,N-dimethyltryptamine, is a lesser-known psychedelic drug of the tryptamine family. [1] It is the 4,5-methylenedioxy derivative of dimethyltryptamine (DMT) and is an analogue of psilocin (4-HO-DMT) and 5-MeO-DMT. [1] The drug was included as an entry in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved), but it was not tested to determine its psychoactive effects and its dose and duration are unknown. [1] Studies in rodents found that its potential hallucinogenic potency is less than that of 4,5-MDO-DiPT but greater than that of 5,6-MDO-DiPT. [2] 4,5-MDO-DMT was first described in the scientific literature by Toni B. Kline and colleagues in 1982. [2]

Contents

See also

References

  1. 1 2 3 4 5 Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN   0-9630096-9-9. OCLC   38503252.
  2. 1 2 3 Kline TB, Benington F, Morin RD, Beaton JM (August 1982). "Structure-activity relationships in potentially hallucinogenic N,N-dialkyltryptamines substituted in the benzene moiety". Journal of Medicinal Chemistry. 25 (8): 908–913. doi:10.1021/jm00350a005. PMID   7120280.